Japan Tissue Engineering Co Rule of 40
The Rule of 40 of Japan Tissue Engineering Co (7774.T) as of Oct 21, 2026 is -36.28 %. In the previous year, Rule of 40 was -12.04 % — a change of 201.30% (lower).
Get this data via API
Financial Data API
Rule of 40
-36.28 %
YoY
201.30%
Last updated:
Rule of 40 of Japan Tissue Engineering Co is 2026 -36.28 % . Rule of 40 of Japan Tissue Engineering Co was 2025 -12.04 % . It decreases by 201.30% lower compared to the previous year.
The Japan Tissue Engineering Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2019
-10.98 JPY
Jan 1, 2020
-12.22 JPY
Jan 1, 2021
-22.94 JPY
Jan 1, 2022
-30.51 JPY
Jan 1, 2023
-39.20 JPY
Jan 1, 2024
29.45 JPY
Jan 1, 2025
-12.04 JPY
Jan 1, 2026
-36.28 JPY
| YEAR | Rule of 40 | YoY |
|---|---|---|
| -36.28 % | +201.30% | |
| -12.04 % | -140.89% | |
| 29.45 % | -175.13% | |
| -39.20 % | +28.47% | |
| -30.51 % | +33.01% | |
| -22.94 % | +87.72% | |
| -12.22 % | +11.34% | |
| -10.98 % | -170.90% | |
| 15.48 % | -75.67% | |
| 63.63 % | -209.13% | |
| -58.31 % | +52.39% | |
| -38.26 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Japan Tissue Engineering Co Stock analysis
What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally.
The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development.
JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Japan Tissue Engineering Co stock
Rule of 40 of Japan Tissue Engineering Co is -36.28 % in 2026.
On Eulerpool you can find the complete historical development of Rule of 40 Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Japan Tissue Engineering Co
All Key Metrics — Japan Tissue Engineering Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth